DrugPatentWatch Database Preview
Sanofi Company Profile
What is the competitive landscape for SANOFI, and what generic alternatives to SANOFI drugs are available?
SANOFI has one hundred and fifty-one approved drugs.
There are seventy-four US patents protecting SANOFI drugs.
There are one thousand four hundred and ninety-eight patent family members on SANOFI drugs in seventy-three countries and one hundred and eighty-six supplementary protection certificates in fifteen countries.
Summary for Sanofi
| International Patents: | 1498 |
| US Patents: | 74 |
| Tradenames: | 126 |
| Ingredients: | 101 |
| NDAs: | 151 |
| Patent Litigation for Sanofi: | See patent lawsuits for Sanofi |
| PTAB Cases with Sanofi as petitioner: | See PTAB cases with Sanofi as petitioner |
Drugs and US Patents for Sanofi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi-aventis Us | SOLIQUA 100/33 | insulin glargine; lixisenatide | SOLUTION;SUBCUTANEOUS | 208673-001 | Nov 21, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;IV (INFUSION) | 021759-002 | Jan 31, 2005 | AP | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Sanofi-aventis Us | SOLIQUA 100/33 | insulin glargine; lixisenatide | SOLUTION;SUBCUTANEOUS | 208673-001 | Nov 21, 2016 | RX | Yes | Yes | 9,533,105 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Sanofi Aventis Us | LANTUS | insulin glargine recombinant | INJECTABLE;INJECTION | 021081-001 | Apr 20, 2000 | RX | Yes | Yes | 7,918,833*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Sanofi Aventis Us | RIFADIN | rifampin | INJECTABLE;INJECTION | 050627-001 | May 25, 1989 | AP | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Sanofi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-005 | Mar 27, 1998 | 5,389,618 | ➤ Sign Up |
| Sanofi Aventis Us | TAXOTERE | docetaxel | INJECTABLE;INJECTION | 020449-004 | Aug 2, 2010 | 5,714,512*PED | ➤ Sign Up |
| Sanofi Aventis Us | ELOXATIN | oxaliplatin | INJECTABLE;IV (INFUSION) | 021759-003 | Nov 17, 2006 | 5,716,988*PED | ➤ Sign Up |
| Sanofi Aventis Us | ALLEGRA HIVES | fexofenadine hydrochloride | TABLET;ORAL | 020872-008 | Jan 24, 2011 | 5,855,912*PED | ➤ Sign Up |
| Sanofi Aventis Us | XYZAL | levocetirizine dihydrochloride | TABLET;ORAL | 022064-001 | May 25, 2007 | 4,525,358 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
| ➤ Subscribe | Oral Solution | 0.5 mg/mL | ➤ Subscribe | 2009-01-14 |
| ➤ Subscribe | Capsules | 0.5 mcg and 2.5 mcg | ➤ Subscribe | 2009-03-25 |
| ➤ Subscribe | Extended-release Tablets | 6.25 mg | ➤ Subscribe | 2006-02-24 |
| ➤ Subscribe | Capsules | 1 mcg | ➤ Subscribe | 2010-02-12 |
| ➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2008-12-04 |
| ➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
| ➤ Subscribe | Oral Suspension | 30 mg/5 mL | ➤ Subscribe | 2010-01-25 |
| ➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
| ➤ Subscribe | Transdermal System | 7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs | ➤ Subscribe | 2014-05-30 |
| ➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2007-10-30 |
| ➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
| ➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2007-12-17 |
| ➤ Subscribe | Injection | 2 mcg/mL, 2 mL ampules | ➤ Subscribe | 2007-10-15 |
| ➤ Subscribe | Extended-release Tablets | 12.5 mg | ➤ Subscribe | 2006-01-19 |
| ➤ Subscribe | Injection | 2 mcg/mL, 1 mL in 2 mL vial | ➤ Subscribe | 2011-12-28 |
| ➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
| ➤ Subscribe | Powder for Oral Suspension | 0.8 g/packet and 2.4 g/packet | ➤ Subscribe | 2009-12-30 |
| ➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
| ➤ Subscribe | Capsules | 0.4 mg | ➤ Subscribe | 2004-12-20 |
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
| ➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
Premature patent expirations for SANOFI
International Patents for Sanofi Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Denmark | 0885961 | ➤ Sign Up |
| Hong Kong | 1016616 | ➤ Sign Up |
| Brazil | PI0408090 | ➤ Sign Up |
| Hong Kong | 1222568 | ➤ Sign Up |
| Slovakia | 177799 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Sanofi Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0035 | France | ➤ Sign Up | PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121 |
| 2002001,C0680967 | Lithuania | ➤ Sign Up | PRODUCT NAME: TELITHROMYCINUM (11,12-DIDEOKSI 3-DE((2,6-DIDEOKSI-3-C-METIL-3-O-METIL-ALFA-L-RIBOHEKSOPIRANOZIL)OKSI) 6-O-METIL 3-OKSO 12,11-(OKSIKARBONIL ((4-(4-(3-PIRIDINIL) 1H-IMIDAZOL-1-IL)BUTIL)IMINO))ERITROMICINAS); REGISTRATION NO/DATE: 01/7551/9 20011107 |
| 80039 | Netherlands | ➤ Sign Up | PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAA T; REGISTRATION NO/DATE: EU/1/97/046/001 - 009 19970827 |
| 00584 | Netherlands | ➤ Sign Up | PRODUCT NAME: LIXISENATIDE; REGISTRATION NO/DATE: EU/1/12/811/001-005 20130201 |
| C0023 | France | ➤ Sign Up | PRODUCT NAME: INSULIN GLARGINE; NAT. REGISTRATION NO/DATE: EU/0/00/134/001 20000609; FIRST REGISTRATION: EU/1/00/134/001 20000609 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
